[go: up one dir, main page]

MXPA05012675A - Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa. - Google Patents

Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.

Info

Publication number
MXPA05012675A
MXPA05012675A MXPA05012675A MXPA05012675A MXPA05012675A MX PA05012675 A MXPA05012675 A MX PA05012675A MX PA05012675 A MXPA05012675 A MX PA05012675A MX PA05012675 A MXPA05012675 A MX PA05012675A MX PA05012675 A MXPA05012675 A MX PA05012675A
Authority
MX
Mexico
Prior art keywords
hydroxyamidine
urokinase
compounds
hydroxyguanidine
urokinase inhibitors
Prior art date
Application number
MXPA05012675A
Other languages
English (en)
Inventor
Katja Wosikowski
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex Ag filed Critical Wilex Ag
Publication of MXPA05012675A publication Critical patent/MXPA05012675A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se relaciona con compuestos novedosos para inhibir al activador de plasminogeno de urocinasa (uPA, por sus siglas en ingles) el cual tiene alta biodisponibilidad y susceptibilidad de administracion oral, y tambien con el uso del mismo como compuestos terapeuticos activos para el tratamiento de trastornos relacionados con urocinasa o/y receptor de urocinasa tales como, por ejemplo, tumores y formacion de metastasis. En particular, la invencion se relaciona con compuestos que contienen grupos hidroxiamidina o hidroxiguanidina.
MXPA05012675A 2003-05-26 2004-05-26 Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa. MXPA05012675A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10323898A DE10323898A1 (de) 2003-05-26 2003-05-26 Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
PCT/EP2004/005682 WO2004103984A1 (de) 2003-05-26 2004-05-26 Hydroxyamidin- und hydroxyguanidin-verbindungen als urokinase-hemmstoffe

Publications (1)

Publication Number Publication Date
MXPA05012675A true MXPA05012675A (es) 2006-02-22

Family

ID=33461890

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012675A MXPA05012675A (es) 2003-05-26 2004-05-26 Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.

Country Status (15)

Country Link
US (3) US7608623B2 (es)
EP (2) EP2243774A1 (es)
JP (1) JP4621676B2 (es)
CN (2) CN101791394A (es)
AU (2) AU2004240771B2 (es)
BR (1) BRPI0410663B8 (es)
CA (1) CA2526989C (es)
DE (1) DE10323898A1 (es)
DK (1) DK1628965T3 (es)
ES (1) ES2550611T3 (es)
HU (1) HUE025940T2 (es)
MX (1) MXPA05012675A (es)
PL (1) PL1628965T3 (es)
PT (1) PT1628965E (es)
WO (1) WO2004103984A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003219039A1 (en) * 2002-03-11 2003-09-22 Curacyte Ag Urokinase inhibitors, production and use thereof
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
DE102004045720A1 (de) * 2004-09-21 2006-03-23 Wilex Ag Stabile Dosierungsform von Phenylalanin-Derivaten
DE102004057195A1 (de) 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
RU2410087C2 (ru) 2005-06-24 2011-01-27 Вилекс Аг Применение ингибиторов урокиназы для лечения и/или предупреждения невропатологических заболеваний
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
US20080226624A1 (en) * 2007-03-07 2008-09-18 Wolfgang Schmalix Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect
WO2008143342A1 (ja) * 2007-05-23 2008-11-27 Dainippon Sumitomo Pharma Co., Ltd. ３－アミノ－２，５－ジオキソピロリジン誘導体の製造方法
US9662308B2 (en) 2008-02-01 2017-05-30 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Orally bioavailable pentamidine prodrugs for the treatment of diseases
DE102008007440A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Aminosäurederivate als Arzneistoffe
DE102008007381A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
CN102319241B (zh) * 2011-07-06 2016-02-10 中山大学 一种针对ccl18靶标的化合物在制备抗乳腺癌药物中的应用
DE102011108346A1 (de) * 2011-07-25 2013-01-31 Philipps-Universität Marburg Verwendung von Hemmstoffen der TMPRSS2 als Arzneimittel
BR112018003232A2 (pt) 2015-10-06 2018-09-25 Redhill Biopharma Ltd terapias de combinação para tratamento de câncer
EP3654979A4 (en) * 2017-07-21 2021-04-14 Redhill Biopharma Ltd. USE OF WX-UK1 AND ITS PRODUCT, WX-671, FOR THE TREATMENT OF NON-CARCINOUS MEDICAL CONDITIONS
BR112022017923A2 (pt) 2020-03-10 2022-10-18 Redhill Biopharma Ltd Tratamento de infecção por coronavírus
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
CN114105910B (zh) * 2021-11-02 2024-04-12 北京悦康科创医药科技股份有限公司 一种羟基脒基苯丙氨酸衍生物、药物组合物与用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE4321444A1 (de) 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
JP2852192B2 (ja) 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
US6624169B1 (en) 1998-07-20 2003-09-23 Wilex Biotechnology Gmbh Urokinase inhibitors
AU9059798A (en) * 1998-09-18 2000-04-10 Pentapharm Ag Urokinase inhibitors
DE10029014A1 (de) 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
US6410005B1 (en) * 2000-06-15 2002-06-25 Pmd Holdings Corp. Branched/block copolymers for treatment of keratinous substrates
CA2408424A1 (en) 2000-06-27 2002-01-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling
ATE517910T1 (de) * 2000-08-11 2011-08-15 Wilex Ag NICHT-KOVALENTE INHIBITOREN VON UROKINASE UND BLUTGEFÄßBILDUNG
NZ547626A (en) 2000-08-11 2007-10-26 Wilex Ag Non-covalent inhibitors of urokinase and blood vessel formation
AU2002227269A1 (en) * 2000-11-07 2002-06-03 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
EP1360493A1 (en) * 2001-02-07 2003-11-12 Graffinity Pharmaceutical Design GmbH Screening method using solid supports modified with self-assembled monolayers
WO2002074756A2 (de) * 2001-03-21 2002-09-26 Pentapharm Ag Urokinase-inhibitoren
CH695999A5 (de) * 2002-02-28 2006-11-15 Wilex Ag Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten.
US7247724B2 (en) * 2002-07-25 2007-07-24 Wilex Ag Method for the production of phenylalanine derivatives

Also Published As

Publication number Publication date
DK1628965T3 (en) 2015-11-02
CA2526989C (en) 2012-12-04
BRPI0410663B1 (pt) 2019-05-21
BRPI0410663B8 (pt) 2021-05-25
AU2009201816A1 (en) 2009-05-28
AU2004240771B2 (en) 2009-02-19
ES2550611T3 (es) 2015-11-11
JP2007513062A (ja) 2007-05-24
BRPI0410663A (pt) 2006-06-20
PT1628965E (pt) 2015-11-04
US20100068272A1 (en) 2010-03-18
CN1795183A (zh) 2006-06-28
US7807681B2 (en) 2010-10-05
CN101791394A (zh) 2010-08-04
CA2526989A1 (en) 2004-12-02
US20060142305A1 (en) 2006-06-29
WO2004103984A1 (de) 2004-12-02
EP1628965A1 (de) 2006-03-01
EP1628965B1 (de) 2015-07-22
AU2004240771A1 (en) 2004-12-02
PL1628965T3 (pl) 2016-02-29
HUE025940T2 (en) 2016-05-30
JP4621676B2 (ja) 2011-01-26
US7608623B2 (en) 2009-10-27
EP2243774A1 (de) 2010-10-27
DE10323898A1 (de) 2004-12-23
US20080261998A1 (en) 2008-10-23
CN1795183B (zh) 2010-04-28

Similar Documents

Publication Publication Date Title
MXPA05012675A (es) Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.
IL260127B (en) mek inhibitors and methods of using them
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
DE60324183D1 (en) Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
YU84603A (sh) Novi inhibitori tirozin kinaze
TW200615266A (en) Organic compounds
TW200510375A (en) New compounds
MY143466A (en) Inhibitors of tyrosine kinases
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
MX2022013615A (es) Inhibidores de macrociclo de peptidilarginina deiminasas.
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
MY138708A (en) Biaryloxymethylarenecarboxylic acids
GB0112348D0 (en) Compounds
AU2003278667A1 (en) Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
SE0302756D0 (sv) Novel Compounds
MXPA05010020A (es) Derivados de oxamida.
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
WO2022140428A3 (en) Inhibitors of peptidylarginine deiminases
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
MX2023011012A (es) Compuestos farmaceuticos como inhibidores de proteasa 19 especifica de ubiquitina (usp19).
PH12021550093A1 (en) Compounds for use in the treatment of fascioliasis

Legal Events

Date Code Title Description
FG Grant or registration